PremiumThe FlyBeiGene receives positive CHMP opinion for Tevimbra BeiGene price target raised to $259 from $207 at Bernstein BeiGene’s Strong Market Position and Growth Potential: A Buy Rating by Reni Benjamin PremiumThe FlyBeiGene granted orphan designation for sonrotoclax BeiGene price target raised to $313 from $259 at Macquarie BeiGene price target raised to $348 from $345 at Guggenheim PremiumCompany AnnouncementsBeiGene’s Earnings Call: Strong Growth and Market Leadership BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $4.74B BeiGene reports Q4 EPS ($1.43), consensus ($1.02) 
